Westin, J., Simmons, G., Bartlett, N. L., Holmes, H., Matasar, M., Yimer, H. A., Gandhi, M., Sharman, J. P., Reshef, R., Merchant, A. A., Linhares, Y., Stevens, D. A., Herrera, A. F., Locke, F. L., Feng, A., Navale, L., Tsai, J., Gall, J. B. L., Burke, J. M. (2025). ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps7085